ClinicalTrials.gg
RecruitingNCT06720571STIM-PRADERUpdated Dec 6, 2024

Effects of Transcutaneous Vagus Nerve Stimulation on Emotion Regulation and Executive Functioning in Prader-Willi Syndrome

An interventional study of Auricular vagal neuromodulation therapy (aVNT) and Sham Auricular vagal neuromodulation therapy (aVNT) in Prader-Willi Syndrome, sponsored by University of Bordeaux. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by University of Bordeaux · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Nov 2023, registered Dec 2024).
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Prader-Willi Syndrome with a site in France — 9 open to participants now, 9 under way, 2 of them phase 3. Prader-Willi Syndrome · France.

Planned enrollment
19th of 23
24 · median 50
Started
2023
with 1 other
No phase
9 of 27
3 open now
Registered
25th of 27
by date
Lead sponsor
1 of 27
University of Bordeaux

Among the 27 studies in Prader-Willi Syndrome with a site in France, this one is the 19th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 25th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 27 studies in Prader-Willi Syndrome with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Prader-Willi Syndrome with a site in France, or all of them as a file.
02

Study summary

The STIM-PRADER study aims to assess the effectiveness of auricular vagal neuromodulation therapy (aVNT) on emotional, behavioral, and cognitive domains impaired in Prader-Willi Syndrome (PWS). Currently, no treatment exists that addresses the multiple alterations associated with this rare neurodevelopmental disorder that significantly impact patients and their families. We will investigate the effects of daily, four-hour aVNT stimulation over a nine-month period on (a) emotion regulation, including assessing the persistence of effects following stimulation; (b) executive functions, including inhibition, flexibility, planning, and updating information in memory; (c) hyperphagia; (d) depression; (e) quality of life; (e) and the threshold at which effects on these dimensions can be observed.

We will conduct a longitudinal multicenter parallel randomized controlled single-blind exploratory trial. Twenty-four adults with PWS and 24 caregivers will be randomly assigned to receive either active or sham stimulation under identical conditions (four hours per day, seven days per week over nine months). The primary outcome, focusing on emotional control, will be assessed every two weeks for both participants and caregivers. Secondary outcomes (executive functions, hyperphagia, depression, and quality of life) will be measured at four time points: pre-intervention, at three months, six months, and at nine months.

As this is the first multicenter randomized controlled trial investigating the effects of aVNT as a treatment in PWS patients, we anticipate witnessing improved emotional regulation and reduced eating disorders, along with enhancements in executive functions and quality of life in the active stimulation group. The findings from this project could support the development of broader therapeutic approaches for other conditions in which behavioral disorders and emotional processing deficits affect patients and their caregivers.

03

Conditions studied

  • Prader-Willi Syndrome

Keywords

  • Prader-Willi Syndrome
  • Vagus nerve stimulation
  • aVNT
  • t-VNS
  • Cognition
  • Executive functions
  • Inhibition
  • Flexibility
  • Planning
  • Updating
  • Emotion regulation
  • Behavior
  • Hyperphagia
  • Quality of life
  • Depression
  • Multicenter randomized controlled trial
  • Caregivers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant with PWS: Age : ≥ 18 years old; Diagnosis of Prader-Willi syndrome with identified genotype; Intellectual Quotient ≥ 55 measured by WAIS-IV (abbreviated version); Pathological or threshold score on at least one of the BRIEF-A subscales; Adults volunteering and able to comply with study procedures; Signature of form; Beneficiary of a social security regime
  • Caregivers: Caregivers involved in the participant's family, medical or institutional environment; Caregiver who has signed the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Participant with PWS: Untreated and unstabilized psychiatric and/or behavioral disorders (psychological decompensation within the last year); Severe visual or hearing impairment; Untreated sleep apnea syndrome; Epileptic seizures; Previous significative abnormality; Adults with pacemakers or defibrillators; Metal or electronic devices implanted in the head; Participation in other research involving an exclusion period still in progress at inclusion; Score ≥ 30 indicating severe depression (BDI-II self-report questionnaire); Pregnant or breast-feeding women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Active stimulation

    Device: Auricular vagal neuromodulation therapy (aVNT)

  • Sham comparator
    Sham stimulation

    Device: Sham Auricular vagal neuromodulation therapy (aVNT)

Interventions

  • DeviceAuricular vagal neuromodulation therapy (aVNT)

    The aVNT device used in our study (Parasym ®) consists of a small portable unit connected to stimulation electrodes placed on the left ear. These electrodes deliver painless electrical microcurrents through the skin to stimulate the auricular branch of the vagus nerve (ABVN). The device parameters will be defined in accordance with the recommendations for use of the Parasym ® device and the pilot studies: frequency of 25 Hz, pulse width of 250 µS, and an intensity of 1 mA to 36 mA. Stimulation sessions will last for four hours each day, each of which can be divided into two sessions and conducted over a period of nine months. Patients will adjust the intensity at each session according to their comfort level, starting with a gradual increase until they feel a slight tingling sensation, followed by a decrease until discomfort disappears completely. Stimulation should take place during a relaxing activity but not should not take place during sleep, meals or major physical activity.

  • DeviceSham Auricular vagal neuromodulation therapy (aVNT)

    The sham stimulation control condition will be performed using the same aVNT Parasym® device under similar conditions (four hours a day, seven days a week, for nine months) but with a different location (without afferent vagus nerve fibers) or a control condition integrated into the device.

06

What researchers measure

Primary outcomes

  1. Evaluation of emotional control and regulation

    The primary outcome measure will focus on assessing emotional control (EC) through a subscale of the BRIEF-A (Behavior Inventory Related to Executive Functions - Adult version).

    Time frame: Every 2 weeks for 11 months (including 3 times before and post-stimulation)

Secondary outcomes

  1. Evaluation of Behavioral manifestations of executive functioning

    BRIEF-A (Behavior Inventory Related to Executive Functions - Adult version)

    Time frame: 4 times (at 0, 3, 6 and 9 months)

  2. Evaluation of Executive functions

    Behavioral inhibition will be assessed using a computerized Go/NoGo task and cognitive flexibility with a computerized voluntary alternation task. Planning abilities will be assessed using the BADS Zoo Test (Behavioral Assessment of Dysexecutive Syndrome - BADS). Finally, the ability to update information will be assessed using an adapted computerized N-2-Back task.

    Time frame: 4 times (at 0, 3, 6 and 9 months)

  3. Evaluation of Hyperphagia

    Hyperphagia will be assessed using a scale derived from the Dykens Hyperphagia Questionnaire: the HQ-CT (Hyperphagia Questionnaire for Use in Prader-Willi Syndrome Clinical Trials)

    Time frame: 4 times (at 0, 3, 6 and 9 months)

  4. Evaluation of Depression

    Depression will be assessed using the Depression Self-Report Questionnaire (Beck Depression Inventory - BDI-II)

    Time frame: 4 times (at 0, 3, 6 and 9 months)

  5. Evaluation of Quality of life

    We will assess the quality of life of participants with PWS using the WHOQOL-BREF questionnaire (World Health Organization Quality of Life-BREF)

    Time frame: 4 times (at 0, 3, 6 and 9 months)

07

Study locations

3 of 4 sites recruiting
  • Reference Center of Prader-Willi Syndrome (PRADORT)
    Bordeaux, 33600, France
    Not yet recruiting
  • Reference Center of Prader-Willi Syndrome (CRMR PRADORT)
    Hendaye, 64700, France
    Recruiting
    • Fabien Mourre, MD, PhD · Contactfabien.mourre@aphp.fr · + 33 05 59 48 08 00
    • Fabien Mourre, MD, PhD · Principal investigator
  • Reference Center of Prader-Willi Syndrome (PRADORT)
    Paris, 75013, France
    Recruiting
    • Christine Poitou-Bernert, MD, PhD · Contactchristine.poitou-bernert@aphp.fr · +33 01 42 17 57 71
    • Christine Poitou-Bernert, MD, PhD · Principal investigator
  • Reference Center of Prader-Willi Syndrome (PRADORT)
    Toulouse, 31000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Mar 2026, 28 months after the start.

Of 19 interventional studies with no phase under Prader-Willi Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 6, 2024
StartActual
Nov 22, 2023
Primary completionEst.
Mar 30, 2026
CompletionEst.
Mar 30, 2026
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06720571
Lead sponsor
University of Bordeaux
Collaborators
John Bost Foundation, CHU Bordeaux, Hendaye hospital, Groupe Hospitalier Pitie-Salpetriere, CHU Toulouse, Prader-Willi Syndrome Association
Responsible party
Virginie Postal (Researcher and Professor, University of Bordeaux) — Principal investigator
First posted
Dec 6, 2024
Start date
Nov 22, 2023
Primary completion
Mar 30, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Dec 6, 2024

Study contacts

Virginie Postal, PhD
Contact
virginie.postal@u-bordeaux.fr
+33 (0)57 57 19 74
Camille Nahon, PhD student, neuropsychologist
Contact
camille.nahon@u-bordeaux.fr
+33 05 57 57 19 64
Virginie Postal, PhD
principal investigator · University of Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion